Researchers found that people receiving a monthly injectable form of buprenorphine, known as SUBLOCADE®, are significantly less likely to relapse into opioid use compared to those on other treatments. In fact, those who adhered to this monthly treatment were 3.5 to 8.1 times less likely to return to opioid use than those who were non-adherent or used different medications for opioid use disorder (OUD). Additionally, this group experienced a 62% reduction in bloodstream infections and fewer healthcare visits, including emergency and outpatient care.

This information is crucial for anyone concerned about the impacts of opioid use disorder on health and longevity. The findings suggest that opting for a monthly injectable treatment could lead to better health outcomes, such as improved recovery rates and fewer complications. This is particularly relevant for individuals struggling with opioid dependence who want to minimize relapse and associated health risks.

The evidence comes from two retrospective studies analyzing data from thousands of patients. The first study looked at over 3,400 patients’ adherence to the injectable treatment and its effects on relapse rates. The second focused on nearly 120,000 patients, comparing infection rates and healthcare utilization. While these studies provide strong insights, they are based on existing health records and claims data, meaning they should be interpreted with caution. The findings are promising but not yet definitive proof of the treatment’s effectiveness in all populations.

If you’re considering treatment options for opioid use disorder, discussing the possibility of a monthly injectable buprenorphine with your healthcare provider may be beneficial. This form of treatment could offer a more stable recovery path and potentially reduce the risk of serious health complications.

Source: globenewswire.com